• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
YU Rongrong,DENG Yiping,LIU Ying,LIN Weiting,QIN Xiaojing,YANG Chengzi,HE Longgang,CHEN Jianyu.Research progress on modern pharmacology of magnololand honokiol in chronic disease[J].Journal Of Pharmaceutical Research,2025,44(9):893-899[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2398times   Download 740次 QR Code for this article
Scan with your phone!
厚朴酚与和厚朴酚对慢性疾病现代药理研究进展
俞榕榕,邓逸苹,刘滢,林苇婷,秦晓静,杨成梓,贺龙刚,陈剑钰
Font:Larger+|Default|Smaller-
(福建中医药大学药学院,福建 福州 350122)
摘要:
厚朴临床常用于治疗胃肠和肺部疾病,厚朴酚与和厚朴酚是厚朴的主要活性成分,近年来大量研究表明二者具有抗炎、抗氧化和抗肿瘤等多种药理作用,而炎症为多种慢性疾病的共病基础,表明其具有治疗多种疾病的潜力,其临床应用仍有提升空间。本文综述了近5年国内外厚朴及其主要活性成分厚朴酚与和厚朴酚治疗慢性疾病的研究进展,发现它们可以从多种途径分别调控免疫紊乱、炎症和氧化应激,从而实现抗炎和抗关节炎;此外,厚朴酚与和厚朴酚还可通过激动糖尿病热门靶点—过氧化物酶体增殖物激活受体γ(PPARγ)进而降低血糖,改善糖尿病并发症,认知障碍及脂代谢紊乱,即便在胰岛素抵抗型小鼠模型中它们仍具有明显降糖作用。本文将深入探讨厚朴酚与和厚朴酚在治疗多种慢性疾病的作用及优势,为拓展厚朴及其活性成分(厚朴酚与和厚朴酚)应用提供依据。
关键词:  厚朴酚  和厚朴酚  厚朴  慢性疾病
DOI:10.13506/j.cnki.jpr.2025.09.011
基金项目:国家自然科学基金项目(No.82474150)
Publication Date:September 25, 2025
Research progress on modern pharmacology of magnololand honokiol in chronic disease
YU Rongrong,DENG Yiping,LIU Ying,LIN Weiting,QIN Xiaojing,YANG Chengzi,HE Longgang,CHEN Jianyu
(School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China)
Abstract:
Magnolia officinalis is often used clinically to treat gastrointestinal and lung diseases. Magnolol and honokiol are the main active ingredients of Magnolia officinalis. In recent years, a large number of studies have shown that they have various pharmacological effects such as anti-inflammatory, antioxidant and anti-tumor.Inflammation is the comorbidity basis of multiple chronic diseases, indicating that it has the potential to treat multiple diseases, and its clinical application still has room for improvement. This article reviews the research progress of magnolia officinalis and its main active ingredients magnolol and honokiol in the treatment of chronic diseases at home and abroad in the past five years. It is found that they can regulate immune disorders, inflammation and oxidative stress from multiple cellular pathways, thereby achieving anti-inflammation and anti-arthritis; In addition,magnolol and honokiol can also lowers blood sugar by stimulating the popular target of diabetes,peroxisome proliferator activated receptor gamma (PPARγ), and improves diabetic complications, cognitive impairment and lipid metabolism disorders. Even in insulin-resistant mouse models, they still have significant blood sugar lowering effect. This article will discuss in detail the role and advantages of magnolol and honokiol in the treatment of various chronic diseases, and provide basis for expanding the application of Magnolia officinalis and its active ingredients (magnolol and honokiol).
Key words:  Magnolol  Honokiol  Magnoliae Officinalis  Chronic diseases
Today's Visits:485    Total Visits:2383197
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.